Abemaciclib: Pharma company lawsuit forces Dutch health agency to reassess cancer drug

The Dutch healthcare procurement agency has said it will reassess the breast cancer drug abemaciclib after being ordered to do so by the court of Amsterdam, in a case brought by pharmaceutical company Eli Lilly.The Dutch National Health Care Institute (Zorginstituut Nederland) decides which new drugs should be funded through the healthcare system, in a similar way to the National Institute for Health and Care Excellence (NICE) for the NHS in England and Wales.The lawsuit was filed in response to the institute’s recommendation to the Dutch health minister not to reimburse the cost of Eli Lilly’s drug abemaciclib (Verzenio) for adults with a certain type of early stage breast cancer, as it did not believe it would improve survival or quality of life.1In the Netherlands expensive new drugs are not automatically covered by health insurance, although they may be covered if the institute makes a positive recommendation to the health…
Read Original Article: Abemaciclib: Pharma company lawsuit forces Dutch health agency to reassess cancer drug »